title: Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats.
abstract: Previous studies proved that food strongly enhanced the bioavailability of vinpocetine. Food may change the pharmacokinetics of a drug by affecting various factors, including gastrointestinal pH. However, the influence of proton pump inhibitor-induced pH alterations on vinpocetine pharmacokinetics is not known. The aim was to evaluate the influence of omeprazole on the pharmacokinetics of oral vinpocetine. One group of male Wistar rats received single oral doses of vinpocetine (2 mg/kg - regimen V). In the second group, omeprazole (10 mg/kg) was administered intraperitoneally for 5 days before vinpocetine administration (regimen OV). For analysis of vinpocetine pharmacokinetics, blood samples were obtained before and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h after vinpocetine administration. Vinpocetine concentrations were measured by high performance liquid chromatography (HPLC). The mean values of AUC(0-t), AUC(0-inf) and C(max) in regimen V were very similar to respective values in regimen OV. The mean T(max) in both regimens was estimated for 1.5 h. There were no statistically significant differences between both regimens. In conclusion, omeprazole did not affect the pharmacokinetic profile of vinpocetine.
authors.affiliation: Department of Pharmacology, Wroclaw Medical University, Mikulicza-Radeckiego 2, PL 50-345 Wrocław, Poland. tsoz@wp.pl
authors.forename: Tomasz
authors.initials: T
authors.lastname: Sozański
authors.forename: Jan
authors.initials: J
authors.lastname: Magdalan
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Trocha
authors.forename: Antoni
authors.initials: A
authors.lastname: Szumny
authors.forename: Anna
authors.initials: A
authors.lastname: Merwid-Ląd
authors.forename: Wojciech
authors.initials: W
authors.lastname: Słupski
authors.forename: Marta
authors.initials: M
authors.lastname: Karaźniewicz-Łada
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Kiełbowicz
authors.forename: Dorota
authors.initials: D
authors.lastname: Ksiądzyna
authors.forename: Adam
authors.initials: A
authors.lastname: Szeląg
mesh_terms: D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D004347:Drug Interactions; D006863:Hydrogen-Ion Concentration; D008297:Male; D009853:Omeprazole / Q000494:pharmacology*; D054328:Proton Pump Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014665:Vasodilator Agents / Q000493:pharmacokinetics*; D014748:Vinca Alkaloids / Q000493:pharmacokinetics*
chemical_list: D054328:Proton Pump Inhibitors; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine; D009853:Omeprazole